Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 674-681 , May 2011

Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States

  • Chitra Hosing

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Chitra Hosing MD, Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030.
    • ,
  • Richard Nash

      Affiliations

    • Clinical Research Division, Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Peter McSweeney

      Affiliations

    • Blood and Marrow Transplant Program, Rocky Mountain Cancer Center, Denver, Colorado
    • ,
  • Shin Mineishi

      Affiliations

    • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
    • ,
  • James Seibold

      Affiliations

    • Division of Rheumatology, University of Michigan, Ann Arbor, Michigan
    • ,
  • Linda M. Griffith

      Affiliations

    • Clinical Immunology Branch, Division of Allergy, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Howard Shulman

      Affiliations

    • Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Ellen Goldmuntz

      Affiliations

    • Clinical Immunology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Maureen Mayes

      Affiliations

    • Division of Rheumatology, University of Texas, Houston, Texas
    • ,
  • Chirag R. Parikh

      Affiliations

    • Department of Medicine, Yale University, New Haven, Connecticut
    • ,
  • Leslie Crofford

      Affiliations

    • Division of Rheumatology, University of Kentucky, Lexington, Kentucky
    • ,
  • Lynette Keyes-Elstein

      Affiliations

    • Senior Statistical Scientist, Rho, Inc, Chapel Hill, North Carolina
    • ,
  • Daniel Furst

      Affiliations

    • Division of Rheumatology, University of California, Los Angeles, California
    • ,
  • Virginia Steen

      Affiliations

    • Division of Rheumatology, Georgetown University, Washington, DC
    • ,
  • Keith M. Sullivan

      Affiliations

    • Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina

Received 4 February 2010 ,Accepted 3 August 2010.

References 

  1. Steen VD, Syzd A, Johnson JP, et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol. 2005;32:649–655
  2. Denton CP. Renal manifestations of systemic sclerosis: clinical features and outcome assessment. Rheumatology (Oxford). 2008;47(Suppl 5):54–56
  3. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66:754–763
  4. Kersting S, Verdonck LF. Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant. 2007;13:638–643
  5. Kersting S, Dorp SV, Theobald M, et al. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant. 2008;14:125–131
  6. Saddadi F, Najafi I, Hakemi MS, et al. Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran. Iran J Kidney Dis. 2010;4:20–26.
  7. Parikh CR, Coca SG. Acute renal failure in hematopoietic cell transplantation. Kidney Int. 2006;69:430–435
  8. Glezerman IG, Jhaveri KD, Watson TH, et al. Chronic kidney disease, thrombotic microangiopathy and hypertension following T cell–depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:976-984.
  9. Zager RA, O’Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989;13:210–216
  10. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110:1388–1396
  11. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum. 2006;54:1982–1986
  12. Craciunescu OI, Steffey BA, Kelsey CR, et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation on the SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial. Int J Radiat Oncol Biol Physics. 2010;in press
  13. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31
  14. Borg M, Hughes T, Horvath N, et al. Renal toxicity after total body irradiation. Int J Radiat Oncol Biol Phys. 2002;54:1165–1173
  15. Van Why SK, Friedman AL, Wei LJ, et al. Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant. 1991;7:383–388
  16. Kal HB, Loes van Kempen-Harteveld M, Heijenbrok-Kal MH, et al. Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation. Strahlenther Onkol. 2006;182:672–679
  17. Kal HB, van Kempen-Harteveld ML. Renal dysfunction after total body irradiation: dose–effect relationship. Int J Radiat Oncol Biol Phys. 2006;65:1228–1232
  18. Levine JM, Lien YH. Antithymocyte globulin–induced acute renal failure. Am J Kidney Dis. 1999;34:1155;(letter)
  19. Wu I, Parikh CR. Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol. 2008;3:1895–1901
  20. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60:577–584
  21. Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008;67:98–104
  22. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004;63:974–981
  23. Haviv YS, Safadi R. Normotensive scleroderma renal crisis: case report and review of the literature. Renal Fail. 1998;20:733–736
  24. Teixeira L, Mahr A, Berezne A, et al. Scleroderma renal crisis, still a life-threatening complication. Ann NY Acad Sci. 2007;1108:249–258
  25. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110–116
  26. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin-converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–357
  27. Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133:600–603
  28. Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41:1613–1619
  29. DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002;46:2983–2989
  30. Strand V. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002;46:2836–2837
  31. Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579–585
  32. Cheng JC, Schultheiss TE, Wong JY. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys. 2008;71:1436–1443
  33. Rabinowe SN, Soiffer RJ, Tarbell NJ, et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood. 1991;77:1837–1844
  34. Krochak RJ, Baker DG. Radiation nephritis: clinical manifestations and pathophysiologic mechanisms. Urology. 1986;27:389–393
  35. Iacopino P, Pucci G, Arcese W, et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant. 1999;24:47–51
  36. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018–2024
  37. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–575
  38. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100
  39. Elliott MA, Nichols WL, Plumhoff EA, et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc. 2003;78:421–430
  40. Choi CM, Schmaier AH, Snell MR, et al. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs. 2009;69:183–198
  41. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–68
  42. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?. Bone Marrow Transplant. 2007;40:709–719
  43. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol. 2004;41:4–14
  44. Hovinga JA, Studt JD, Alberio L, et al. von Willebrand factor–cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol. 2004;41:75–82
  45. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:496–507
  46. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600
  47. Manadan AM, Harris C, Block JA. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum. 2005;34:683–688
  48. Nanke Y, Akama H, Yamanaka H, et al. Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy. Am J Med Sci. 2000;320:348–351
  49. Kapur A, Ballou SP, Renston JP, et al. Recurrent acute scleroderma renal crisis complicated by thrombotic thrombocytopenic purpura. J Rheumatol. 1997;24:2469–2472
  50. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Biol Blood Marrow Transplant. 2010;16:S48–S56
  51. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73;(editorial)

 Financial disclosure: See Acknowledgments on page 679.

PII: S1083-8791(10)00341-1

doi: 10.1016/j.bbmt.2010.08.003

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 674-681 , May 2011

Article Tools

* Image Usage & Resolution